Breaking News, Collaborations & Alliances

BMS, uniQure Enter Cardiovascular R&D Pact

Gains access to uniQure’s gene therapy technology platform for multiple targets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb and uniQure entered an agreement that provides BMS with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular disease. The collaboration includes uniQure’s gene therapy program for congestive heart failure that aims to restore the heart’s ability to synthesize S100A1, a calcium sensor and master regulator of heart function. The agreement also includes the potential for target-exclusive collaboration in other disease areas on te...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters